Filtered By:
Condition: Aortic Stenosis

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 1228 results found since Jan 2013.

Repositionable Percutaneous Aortic Valve Implantation with the Lotus Valve: 30-Day and 1-Year Outcomes in 250 High-Risk Surgical Patients.
CONCLUSIONS: Lotus Valve implantation produced excellent valve haemodynamics, minimal PVL, sustained significant improvement in functional status, and good clinical outcomes 1 year post-implant. PMID: 28555592 [PubMed - as supplied by publisher]
Source: EuroIntervention - June 1, 2017 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

FDA clears Medtronic ’ s CoreValve Evolut TAVR in intermediate risk patients
Medtronic (NYSE:MDT) said today it won expanded FDA approval for its CoreValve Evolut transcather aortic valve replacement platform, now indicated for patients with symptomatic severe aortic stenosis who are at an intermediate risk for open heart surgery. The Fridley, Minn.-based company said that patients at intermediate risk for open-heart surgery have a mortality risk of greater than or equal to 3% at 30 days following the procedure. “Patients at intermediate risk for open-heart surgery account for a large portion of the severe aortic stenosis population. We are delighted to take the self-expanding CoreValve Evo...
Source: Mass Device - July 10, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves Medtronic Source Type: news

Outcome of transcatheter aortic valve implantation in high risk patients with severe aortic stenosis
Conclusion TAVI is a safe and effective procedure in selected high-risk patients with severe symptomatic aortic stenosis without significant difference between used valves.
Source: The Egyptian Heart Journal - August 7, 2017 Category: Cardiology Source Type: research

Increased apical rotation in patients with severe aortic stenosis assessed by three-dimensional speckle tracking imaging
ConclusionsIn severe AS patients, impaired GLS existed although LVEF was preserved. However, LV rotation was increased in patients with severe AS probably to maintain the LV stroke volume.
Source: Journal of Echocardiography - August 11, 2017 Category: Cardiology Source Type: research

Comparison of continous-wave Doppler ultrasound monitor and echocardiography to assess cardiac output in intensive care patients.
CONCLUSIONS: SV (and thus cardiac output) measured using the USCOM correlated well with echocardiographic cardiac output measurement, which suggests that the USCOM could be a valuable haemodynamic tool for assessment of cardiac output and fluid responsiveness in critically ill patients if patients with aortic stenosis are excluded. Inotropy, as a parameter of low cardiac output, was not useful in this cohort of patients. PMID: 28866972 [PubMed - in process]
Source: Critical Care and Resuscitation - September 6, 2017 Category: Intensive Care Tags: Crit Care Resusc Source Type: research

SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve
ConclusionIn SOURCE 3, we observe a low complication rate and mortality at 1  year. Given the low incidence of higher degree paravalvular leakages, this variable did no longer affect outcome. Clinicaltrial.gov number: NCT02698956.
Source: European Heart Journal - June 12, 2017 Category: Cardiology Source Type: research

Usefulness of the CHA2DS2-VASc Score to Predict Outcome in Patients Who Underwent Transcatheter Aortic Valve Implantation
Risk assessment for transcatheter aortic valve implantation (TAVI) patients remains challenging, especially in elderly and high-risk candidates. Although several risk factors contribute to increased morbidity and mortality after TAVI, simple risk scores for routine use are lacking. Applying the CHA2DS2-VASC (congestive heart failure, hypertension, age  ≥ 75 years, diabetes, prior stroke, vascular disease, age 65–74 years, sex [female] category) score as a novel risk stratification tool for conditions other than atrial fibrillation and stroke prevention has been previously examined; however, its usefulness in a popu...
Source: The American Journal of Cardiology - October 19, 2017 Category: Cardiology Authors: Katia Orvin, Amos Levi, Uri Landes, Tamir Bental, Alexander Sagie, Yaron Shapira, Hana Vaknin-Assa, Abid Assali, Ran Kornowski Source Type: research

Postoperative Reverse Remodeling and Symptomatic Improvement in Normal-Flow Low-Gradient Aortic Stenosis After Aortic Valve Replacement Valvular Heart Disease
Conclusions— Patients with NFLG had less severe AS and LV remodeling than patients with normal-flow high-gradient. Furthermore, NFLG patients experienced less reverse remodeling but the same symptomatic benefit. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT02316587.
Source: Circulation: Cardiovascular Imaging - December 8, 2017 Category: Radiology Authors: Carter-Storch, R., Moller, J. E., Christensen, N. L., Irmukhadenov, A., Rasmussen, L. M., Pecini, R., Ovrehus, K. A., Sondergard, E. V., Marcussen, N., Dahl, J. S. Tags: Valvular Heart Disease, Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Source Type: research

Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap
Conclusions The safety and efficacy results of this study support the use of the Evolut PRO System for the treatment of severe symptomatic aortic stenosis in patients who are at increased surgical risk, resulting in excellent hemodynamics and minimal paravalvular leak (The Medtronic TAVR 2.0 US Clinical Study; NCT02738853)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 15, 2018 Category: Cardiology Authors: Forrest, J. K., Mangi, A. A., Popma, J. J., Khabbaz, K., Reardon, M. J., Kleiman, N. S., Yakubov, S. J., Watson, D., Kodali, S., George, I., Tadros, P., Zorn, G. L., Brown, J., Kipperman, R., Saul, S., Qiao, H., Oh, J. K., Williams, M. R. Tags: Structural: Focus on TAVR Source Type: research

Layer ‐specific deformation analysis in severe aortic valve stenosis, primary mitral valve regurgitation, and healthy individuals validated against invasive hemodynamic measurements of heart function
ConclusionLayer‐specific myocardial strain (LSS) patterns differed in patients with severe AS, significant MR, and healthy individuals with highest values in MR. Strain irrespective of layer assessed was associated with LV wall stress but seemed less related to contractility and unrelated to stroke work in the setting of normal LVEF.
Source: Echocardiography - January 21, 2018 Category: Cardiology Authors: Rine Bakkestr øm, Nicolaj L. Christensen, Emil Wolsk, Ann Banke, Jordi S. Dahl, Mads J. Andersen, Finn Gustafsson, Christian Hassager, Jacob E. Møller Tags: ORIGINAL INVESTIGATION Source Type: research

Treatment of Aortic Stenosis With a Self-Expanding, Resheathable Transcatheter Valve: One-Year Results of the International Multicenter Portico Transcatheter Aortic Valve Implantation System Study Structural Heart Disease
Conclusions— The Portico TAVI system is safe and effective at 1 year, yielding low mortality and stroke rates in high-risk patients with severe AS. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique identifier: NCT01493284.
Source: Circulation: Cardiovascular Interventions - February 14, 2018 Category: Cardiology Authors: Linke, A., Holzhey, D., Mollmann, H., Manoharan, G., Schafer, U., Frerker, C., Worthley, S. G., van Boven, A. J., Redwood, S., Kovac, J., Butter, C., Sondergaard, L., Lauten, A., Schymik, G., Walther, T. Tags: Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Structural Heart Disease Source Type: research

Oral anti-Xa anticoagulation after Trans-Aortic Valve Implantation for Aortic Stenosis: The randomized ATLANTIS trial
Conclusions ATLANTIS tests the superiority of an apixaban-based strategy versus the recommended standard of care strategy to reduce the risk of post-TAVR thromboembolic and bleeding complications in an all comer population.
Source: American Heart Journal - March 10, 2018 Category: Cardiology Source Type: research

One-year outcomes of patients with severe aortic stenosis and an STS-PROM of less than three percent in the SURTAVI trial.
CONCLUSIONS: Among patients at intermediate surgical risk but with STS PROM<3%, TAVI may achieve superior clinical outcomes compared to SAVR. These findings support the need for an adequately powered randomized trial to compare TAVI with SAVR in patients at low operative risk. PMID: 29992904 [PubMed - as supplied by publisher]
Source: EuroIntervention - July 12, 2018 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
Publication date: November 2018Source: American Heart Journal, Volume 205Author(s): Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. DangasTranscatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate...
Source: American Heart Journal - August 30, 2018 Category: Cardiology Source Type: research

Transcatheter Aortic Valve Implantation using ACURATE neo in bicuspid and tricuspid aortic valve stenosis: a propensity matched analysis of an European experience.
CONCLUSIONS: this preliminary analysis shows that the use of ACURATE neo in bicuspid aortic valves is feasible and has acceptable 30-days outcome. Larger studies are needed to confirm our preliminary findings. PMID: 30375336 [PubMed - as supplied by publisher]
Source: EuroIntervention - November 1, 2018 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research